JP2021516537A5 - - Google Patents

Info

Publication number
JP2021516537A5
JP2021516537A5 JP2020543219A JP2020543219A JP2021516537A5 JP 2021516537 A5 JP2021516537 A5 JP 2021516537A5 JP 2020543219 A JP2020543219 A JP 2020543219A JP 2020543219 A JP2020543219 A JP 2020543219A JP 2021516537 A5 JP2021516537 A5 JP 2021516537A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
antibody
antigen
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020543219A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021516537A (ja
JP7458567B2 (ja
Filing date
Publication date
Priority claimed from GBGB1803892.7A external-priority patent/GB201803892D0/en
Application filed filed Critical
Publication of JP2021516537A publication Critical patent/JP2021516537A/ja
Publication of JP2021516537A5 publication Critical patent/JP2021516537A5/ja
Application granted granted Critical
Publication of JP7458567B2 publication Critical patent/JP7458567B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020543219A 2018-03-12 2019-03-12 C-met結合剤 Active JP7458567B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB1803892.7 2018-03-12
GBGB1803892.7A GB201803892D0 (en) 2018-03-12 2018-03-12 C-met binding agents
GB1812487.5 2018-07-31
GBGB1812487.5A GB201812487D0 (en) 2018-03-12 2018-07-31 C-Met binding agents
GBGB1816841.9A GB201816841D0 (en) 2018-03-12 2018-10-16 C-met binding agents
GB1816841.9 2018-10-16
PCT/EP2019/056178 WO2019175186A1 (en) 2018-03-12 2019-03-12 Anti c-met antibodies

Publications (3)

Publication Number Publication Date
JP2021516537A JP2021516537A (ja) 2021-07-08
JP2021516537A5 true JP2021516537A5 (cg-RX-API-DMAC7.html) 2022-05-19
JP7458567B2 JP7458567B2 (ja) 2024-04-01

Family

ID=61972884

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020543219A Active JP7458567B2 (ja) 2018-03-12 2019-03-12 C-met結合剤

Country Status (8)

Country Link
US (3) US11673960B2 (cg-RX-API-DMAC7.html)
EP (1) EP3765509A1 (cg-RX-API-DMAC7.html)
JP (1) JP7458567B2 (cg-RX-API-DMAC7.html)
CN (2) CN111819200B (cg-RX-API-DMAC7.html)
AU (2) AU2019233511B2 (cg-RX-API-DMAC7.html)
CA (1) CA3092526A1 (cg-RX-API-DMAC7.html)
GB (3) GB201803892D0 (cg-RX-API-DMAC7.html)
WO (1) WO2019175186A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201803892D0 (en) 2018-03-12 2018-04-25 Ultrahuman Six Ltd C-met binding agents
GB201906685D0 (en) 2019-05-13 2019-06-26 Ultrahuman Six Ltd Activatable protein constructs and uses thereof
IL296519A (en) * 2020-06-02 2022-11-01 Teijin Pharma Ltd Anti-igf-1 receptor humanized antibody
JP7510518B2 (ja) * 2020-09-01 2024-07-03 レメゲン シーオー.,エルティーディー. 抗c-Met抗体薬物複合体及びその応用
EP4232087A4 (en) * 2020-10-21 2024-10-09 Immune-ONC Therapeutics, Inc. NOVEL ANTI-LILRB2 ANTIBODIES AND DERIVED PRODUCTS
AR125473A1 (es) * 2021-04-29 2023-07-19 Abbvie Inc Conjugados de anticuerpo anti-c-met y fármaco
CN115724970B (zh) * 2022-07-27 2023-10-20 生工生物工程(上海)股份有限公司 一种特异性结合e-cad多肽的结合蛋白及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2383295T3 (en) * 2003-12-10 2015-06-15 Squibb & Sons Llc Ip-10 antibodies and uses thereof
JO3076B1 (ar) * 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
PA8849001A1 (es) 2008-11-21 2010-06-28 Lilly Co Eli Anticuerpos de c-met
US8545839B2 (en) 2008-12-02 2013-10-01 Pierre Fabre Medicament Anti-c-Met antibody
AR074439A1 (es) * 2008-12-02 2011-01-19 Pf Medicament Anticuerpo anti-cmet (receptor c-met)
US20140112911A9 (en) 2008-12-02 2014-04-24 Liliane Goetsch Novel anti-cmet antibody
BRPI1015234A2 (en) * 2009-06-22 2018-02-20 Medimmune Llc fc regions designed for site specific conjugation.
HK1201855A1 (en) * 2011-11-01 2015-09-11 Bionomics, Inc. Antibodies and methods of treating cancer
TWI593705B (zh) * 2011-12-28 2017-08-01 Chugai Pharmaceutical Co Ltd Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient
CN104321322A (zh) * 2012-03-30 2015-01-28 理森制药股份公司 作为c-met蛋白激酶调节剂的新型3,5-二取代-3h-咪唑并[4,5-b]吡啶和3,5-二取代-3h-[1,2,3]三唑并[4,5-b]吡啶化合物
CA2869316C (en) * 2012-05-09 2016-12-20 Eli Lilly And Company Anti-c-met antibodies
CN106458916A (zh) * 2014-03-11 2017-02-22 西奈山伊坎医学院 受限制的三环磺酰胺
GB201803892D0 (en) 2018-03-12 2018-04-25 Ultrahuman Six Ltd C-met binding agents

Similar Documents

Publication Publication Date Title
JP2021519100A5 (cg-RX-API-DMAC7.html)
JP2021513323A5 (cg-RX-API-DMAC7.html)
JP2021515541A5 (cg-RX-API-DMAC7.html)
JP2025000787A5 (cg-RX-API-DMAC7.html)
JP2021515542A5 (cg-RX-API-DMAC7.html)
JP2021515544A5 (cg-RX-API-DMAC7.html)
JP2020531048A5 (cg-RX-API-DMAC7.html)
JP2024513921A5 (cg-RX-API-DMAC7.html)
JP2020514277A5 (cg-RX-API-DMAC7.html)
RU2020109544A (ru) Связывающие агенты
JP2022553908A5 (cg-RX-API-DMAC7.html)
JP2019501883A5 (cg-RX-API-DMAC7.html)
JP2022532534A5 (cg-RX-API-DMAC7.html)
JP2017149720A5 (cg-RX-API-DMAC7.html)
JP2020504076A5 (cg-RX-API-DMAC7.html)
JP2016509014A (ja) 新規の多特異的構成物
RU2019121086A (ru) Иммунотерапия с применением антител, связывающих лиганд 1 белка программируемой смерти клеток (PD-L1)
RU2017145150A (ru) Антитело против pdl-1, его фармацевтическая композиция и применение
JP2018506961A5 (cg-RX-API-DMAC7.html)
JP2020534351A5 (cg-RX-API-DMAC7.html)
JP2023516004A5 (cg-RX-API-DMAC7.html)
US20250034273A1 (en) Composition of multispecific antibodies targeting cadherin-17-expressing tumors and method of making and using thereof
JP2010509931A5 (cg-RX-API-DMAC7.html)
JP2020521504A (ja) 抗cd40抗体、その抗原結合フラグメント、およびその医学的使用
JP2021534797A5 (cg-RX-API-DMAC7.html)